Research programme: LDL receptor-transferrin fusion protein - Shire Pharmaceuticals

Drug Profile

Research programme: LDL receptor-transferrin fusion protein - Shire Pharmaceuticals

Alternative Names: LDL receptor-transferrin fusion protein research programme - Transkaryotic Therapies; LDL receptor-transferrin fusion protein research programme: Shire Pharmaceuticals; LDL-cholesterol lowering therapies research programme - Transkaryotic Therapies; LDLR/TF; Research programme: LDL-cholesterol lowering therapies - Shire Pharmaceuticals; TX-1501

Latest Information Update: 19 Mar 2010

Price : $50

At a glance

  • Originator Shire Pharmaceuticals Group
  • Class Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Hyperlipoproteinaemia type II

Most Recent Events

  • 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
  • 16 Feb 2005 Preclinical trials in Familial hypercholesterolaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top